November 27 Product: Orphan Pharmaceuticals Rapiblyk Indication: Atrial fibrillation and atrial flutter in critical care Vienna-based AOP Orphan Pharmaceuticals on Wednesday won the FDAs approval for Rapiblyk (landiolol) for the treatment of atrial fibrillation and atrial flutter in the critical care setting
Ouabain, a natural compound belonging to the cardiac glycosides family, reduces cell survival through apoptotic pathway in human senescent cells induced by genotoxic stress (Etoposide, Doxorubicin and Palbociclib), OIS, or replicative exhaustion
Better positioned for life after the medication
Fees already paid are non-refundable
Der Player (The Player) is a restaurant, bar, games lounge, and nightclub all rolled into one
Physician-supervised weight loss takes the guesswork and frustration out of achieving a healthy weight